Nobivac NXT HCPCh

Opinion

EMA has issued an opinion on this medicine

feline calicivirosis, feline rhinotracheitis, feline panleucopenia and feline chlamydiosis (live) vaccine

Overview

On 21 May 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HCPCh, lyophilisate and solvent for suspension for injection, intended for cat. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobivac NXT HCPCh is an immunological veterinary medicinal product (vaccine) containing feline herpesvirus 1, strain G2620A (live), feline calicivirus, strain F9 (live), feline panleucopenia virus, strain MW-1 (live) and Chlamydia felis, strain Baker (live) as the active substances.

The benefits of Nobivac NXT HCPCh are its efficacy for the active immunisation of cats:

• to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV);
• to reduce clinical signs and virus excretion caused by infection with feline calicivirus (FCV);
• to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPL);
• to reduce clinical signs and bacterial excretion caused by infection with Chlamydia felis;

The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination or 3 years after re-vaccination for FHV and FCV; 3 years for FPL and 1 year for Chlamydia felis.

Nobivac NXT HCPCh is generally well tolerated at the recommended dose. The most common side effects are injection site swelling and elevated temperature (common). Limping is observed very rarely.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HCPCh and therefore recommends the granting of the marketing authorisation.

---

Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

CVMP summary of positive opinion for Nobivac NXT HCPCh

Adopted Reference Number: EMA/CVMP/106114/2026

Product details

• Name of medicine:
  Nobivac NXT HCPCh
• Active substance:
  • chlamydia felis, strain Baker, live
  • felid herpesvirus 1, strain G2620A, Live
  • feline calicivirus (FCV), strain F9, live
  • feline panleucopenia virus (FPL), strain MW-1, live
• International non-proprietary name (INN) or common name:
  feline calicivirosis, feline rhinotracheitis, feline panleucopenia and feline chlamydiosis (live) vaccine
• Species:
  Cats
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI06AF01
• EMA product number:
  EMEA/V/C/006703
• Marketing authorisation applicant:
  Intervet International BV
• Opinion adopted:
  21/05/2026
• Opinion status:
  Positive